The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli ...

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

The announcement could shake up the market for such injections, since the shortage designation allowed compounding pharmacies ...

NHS England has proposed a phased rollout of Eli Lilly’s obesity injection Mounjaro (tirzepatide), prioritizing patients with ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...